Pharma News
Approval of Eli Lilly's Alzheimer Drug Donanemab Delayed as FDA Seeks More Information
![](https://meefro.com/wp-content/uploads/2024/03/Approval-of-Eli-Lilly039s-Alzheimer-Drug-Donanemab-Delayed-as-FDA-780x470.png)
Because of the unique trial design of the Phase III TRAILBLAZER-ALZ 2 study, the FDA is seeking additional input regarding the safety and efficacy of donanemab for the treatment of early symptomatic Alzheimer disease.
Source link
#Approval #Eli #Lilly039s #Alzheimer #Drug #Donanemab #Delayed #FDA #Seeks #Information